Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy

In 2017, immune response evaluation criteria in solid tumors (iRECIST) were introduced to validate radiologic and clinical interpretations and to better analyze tumor’s response to immunotherapy, considering the different time of following and response, between this new therapy compared to the stand...

Descripción completa

Detalles Bibliográficos
Autores principales: Ippolito, Davide, Maino, Cesare, Ragusi, Maria, Porta, Marco, Gandola, Davide, Franzesi, Cammillo Talei, Giandola, Teresa Paola, Sironi, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173324/
https://www.ncbi.nlm.nih.gov/pubmed/34131564
http://dx.doi.org/10.5306/wjco.v12.i5.323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173324/
https://www.ncbi.nlm.nih.gov/pubmed/34131564
http://dx.doi.org/10.5306/wjco.v12.i5.323

Ejemplares similares